Business Wire

VOOPOO

20.4.2022 06:10:47 CEST | Business Wire | Press release

Share
VOOPOO & ZOVOO to Meet You at National Convenience Show Birmingham 2022

VOOPOO, leading vape brand, along with its sister brand ZOVOO, is looking forward to meeting you at the National Convenience Show Birmingham 2022 on April 25-27.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220414005472/en/

The National Convenience Show Birmingham is not only the largest retail show in the UK, but also the most professional world-class event in the world’s retail industry. This year, the event will gather 1,000+ global vendors to share cutting-edge consumer insights and commercial trends, and discuss hot topics such as technology, sustainable development, food hygiene and health, and social media. 90,000+ professional visitors are expected to visit the event.

As the leader of vape technology, VOOPOO and ZOVOO will feature three new products of the year in a 25sqm uniquely-designed booth and showcase new technological breakthroughs and smarter experience in the vape industry. On this occasion, VOOPOO looks forward to establishing connections with more excellent partners, peer brands and users, to jointly develop the market.

ARGUS GT 2, a member of VOOPOO’s high-end ARGUS series and the first MOD product in 2022, will be exhibited at the event. While inheriting the classic style of ARGUS GT, ARGUS GT 2 also provides a fully upgraded professional vape experience, a masculine aesthetic design and an improved collision-proof performance to satisfy massive clouds lovers and those vapers who pursue intensive explosion, high performance and high durability. It is poised to define a new height of user experience.

Powerful TPP vape platform, high power and massive clouds

ARGUS GT 2 is compatible with VOOPOO’s universal TPP vape platform, and with a maximum output power of 200W. The moment the ignition button is pressed, massive clouds will volcanically spew out, bringing users the ultimate enjoyment of taste and the strongest visual pleasure. In addition, with a 200W stable output, users are allowed to enjoy the luxurious experience in a leisurely manner.

Top water, dust and collision-proof body to withstand extreme outdoor scenarios

ARGUS GT 2 has obtained the IP68 rating, the highest rating of protection against water, dust and collision. After thousands of tests, the team for ARGUS GT 2 has created a powerful double-layer waterproof, dust-proof, frost-proof, and collision-proof body that can withstand various extreme outdoor environments like temperatures ranging from minus 20°C to 60°C without affecting its performance. Such a hard and durable ARGUS GT 2 will definitely become the best choice for outdoor vapers.

Innovative volcano crater design to guarantee both massive clouds and leak-proofness

Featured with massive clouds, ARGUS GT 2 comes with the MAAT TANK NEW, which has the unique two-way volcano crater airflow design that can increase the airflow rate by 60% and produce thicker clouds at a higher speed; at the same time, it can better drain the condensed liquid to the isolation section at the bottom, so as to create the ultimate leak-proof experience.

Top GENE.TT 2.0 chip to enable new experience of all-scenario intelligence

ARGUS GT 2 features GENE.TT 2.0 technology and is equipped with an upgraded smart chipset which can automatically match power, and supports multi-mode switching between Smart, RBA, Turbo and TC, allowing vapers to easily control their daily experience. In addition, it adopts a hidden 3A TYPE-C fast charging design, and the charging speed is also improved by 30%. VOOPOO products are rich in color and unique in design. ARGUS GT 2 to be displayed this time is no exception. It will offer five new colors including carbon fiber grey, lime green, and dark blue. This perfect fusion of technology and design will surely bring another surprise to the industry.

As a disruptor in the POD market, ZOVOO will bring DRAGBAR 600s, the first disposable vape with a light bar. The DRAGBAR series have been loved by global users since their launch. The innovative use of ethyl maltol to provide the sweetness in e-liquid can effectively avoid sugar addiction which causes harm to the human body, and are popular among vapers who favor sugar-free and low-sugar e-liquid. What kind of disruptive technology will the DRAGBAR 600s present at the show? In addition to ARGUS GT 2, what new surprises will VOOPOO's other two mysterious new products bring to the industry? Let's wait and see at Booth E20 of National Convenience Show Birmingham 2022 from April 25 to 27!

About VOOPOO

Founded in 2017, VOOPOO has rapidly grown and recognized by vapers from around the world with its DRAG series. VOOPOO is a high-tech enterprise integrating R&D, design, production and brand operation. It has four flagship product series: DRAG, VINCI, ARGUS and V Series, altogether providing consumers with a safe, reliable and diverse all-scenario product ecosystem. Currently, VOOPOO products are sold in more than 70 countries and regions in North America, Europe and Asia. VOOPOO will pursue long-term value and strengthen exchanges and cooperation in technology, brand, and supply chain, and promote the innovation and development of the vape industry. For more information, please visit https://www.voopoo.com/ and follow our Instagram, Facebook and TikTok.

WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye